|A.M.S. Mayer, Ph.D.
Professor of Pharmacology
Department of Pharmacology
Phone: (630) 515-6951
As of February 2013 marine-derived compounds which have been FDA-approved or are in Phase III, II or I of drug development (as determined at http://clinicaltrials.gov/) and are part of the global marine pharmaceutical clinical pipeline are shown below. Since A.M.S. Mayer, K.B. Glaser, C. Cuevas, R.S. Jacobs, W. Kem, R.D. Little, J. M McIntosh, D.J. Newman, B.C. Potts and D. E. Shuster, Trends in Pharmacological Sciences, 31:255-265, 2010 ) was published, clinical trials with Soblidotin (TZT 1027), Tasidotin, Synthadotin (ILX-651), Hemiasterilin (E7974), Elisidepsin (Irvalec®) and Pseudopterosin have been completed or discontinued (See http://clinicaltrials.gov/).
Abbreviations: FDA: Food and Drug Administration, www.fda.gov; NA: not available; NCI: National Cancer Institute; UCHSC: University of Colorado Health Sciences Center
a The marine pharmaceutical pipeline consists of natural products, analogs or derivatives of compounds produced by this marine organism or a symbiont (e.g. cyanobacterium).
b Ongoing clinical/total trials as reported at http://www.clinicaltrials.gov/ in February 2013
1 Bedford Laboratories: http://www.bedfordlabs.com/our_products/online_catalog/products/cytarabine.html/;
4 Eisai Inc.:http://us.eisai.com/section.asp?ID=287;
5 GlaxoSmithKline: http://www.gsk.com/;
7 Seattle Genetics: http://www.seattlegenetics.com/pipeline;
8 Nereus Pharmaceuticals, Inc.:http://www.nereuspharm.com/
9Celldex Therapeutics, Inc.: http://www.celldextherapeutics.com/;
10National Cancer Institute.: http://www.cancer.gov/;
Copyright © 2005-2013 Midwestern University. Last Rev. 03/06/2013. Direct questions or comments to Site Coordinator